

08-16-06

LFE

Please type a plus sign (+) inside this box ☐

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-00.
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number

10/575,291

Filing Date

April 11, 2004

First Named Inventor

Kingston Mills

Group/Art Unit

Unassigned

Examiner Name

Unassigned

Total Number of Pages in This Submission

Attorney Docket Number

43369-0001

ENCLOSURES (check all that apply)☐ Fee Transmittal Form☐ Fee Attached☐ Amendment / Response☐ After Final☐ Version With Markings Showing
Changes☐ Affidavits/declaration(s)☐ Extension of Time Request☒ Information Disclosure Statement w/11
References☐ Certified Copy of Priority Document(s)☐ Response to Missing Parts/ Incomplete
Application☐ Response to Missing
Parts under 37 CFR
1.52 or 1.53☐ Copy of Notice☐ Copy of an Assignment☐ Drawing(s)☐ Licensing-related Papers☐ Petition Routing Slip (PTO/SB/69)
and Accompanying Petition☐ Petition to Convert to a
Provisional Application☐ Power of Attorney, by Assignee to
Exclusion of Inventor Under 37 C.F.R.
§3.71 With Revocation of Prior Powers☐ Terminal Disclaimer☐ Small Entity Statement☐ Request for Refund☐ After Allowance Communication to
Group☐ Appeal Communication to Board of
Appeals and Interferences☐ Proprietary Information☐ Status Letter☐ ADDITIONAL ENCLOSURE(S)
(PLEASE IDENTIFY BELOW):☒ RETURNED STAMPED POSTCARD

Remarks

**AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN
CONNECTION WITH THIS PAPER, REFERENCING ATTORNEY'S DOCKET NO. 43369-0001****SIGNATURE OF APPLICANT, ATTORNEY OR AGENT**

Firm or

HELLER EHRMAN LLP

JAMES A. FOX (Reg. No. 38,455)

Individual name

275 Middlefield Road, Menlo Park, California 94025

Telephone: (650) 324-7000

Facsimile: (650) 324-0638

Signature



Date

August 14, 2006

Customer Number:


25213

CERTIFICATE OF EXPRESS MAILINGI hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: **MAIL STOP xxxxx**, Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on this date: **August 14, 2006.x**Express Mail Label **EV 765 972 675 US**

Typed or printed name

ELENA TORRES

Signature





Date

August 14, 2006

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES C COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop ____, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

5



CERTIFICATE OF EXPRESS MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA on the date indicated below.			
Express Mail Label: EV 765 972 675 US			
Typed or print name	Elena Torres		
Signature		Date	August 14, 2006

PATENT

Attorney Docket No.: 43369-0001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Kingston Mills et al.

Application No.: 10/575,291

Filed: April 11, 2004

Title: FILAMENTOUS HAEMAGGLUTININ IN THE
TREATMENT AND/OR PROPHYLAXIS OF
IMMUNE-MEDIATED DISORDERS

Art Unit: Unassigned

Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §1.97

Mail Stop: AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application, and all additional publications other than U.S. patents and U.S. patent application publications. 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☒ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

- ☐ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No.: 43369-0001).

Respectfully submitted,

HELLER EHRMAN LLP

By: 

James A. Fox
Reg. No.: 38,455

Dated: August 14, 2006

HELLER EHRMAN LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: 1.650.324.7115
Facsimile: 1.650.324.0638
Customer No.: 25213

**INFORMATION DISCLOSURE
STATEMENT**
PTO-1449
ATTY. DOCKET NO.

43369-0001

SERIAL NO.

10/575,291

APPLICANT: Kingston Mills et al.

FILING DATE: 4/11/2004

GROUP: Unassigned

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	4,784,589	11/15/1988	Robinson et al.	424	9	
	4,997,915	05/05/1991	Tan et al.	530	396	
	5,681,571	10/28/1997	Holmgren et al.	424	236	
	5,725,860	03/10/1998	Elliott	424	240.1	
	5,728,385	03/17/1998	Classen	424	201.1	
	6,051,240	04/18/2000	Suehara et al.	424	240.1	
	6,153,203	11/28/2000	Holmgren et al.	424	236.1	
	6,288,214	11/11/2001	Hook et al.	530	387.1	
	6,322,796	11/27/2001	Holmgren et al.	424	236.1	
	6,403,080	06/11/2002	Segal	424	93.1	
	6,632,436	10/14/2003	Segal	424	192.1	
	6,365,163	04/02/2002	Holmgren et al.	424	236.1	
	6,638,739	10/28/2003	Classen	435	69.3	
	6,660,261	12/09/2003	Mielcarek et al.	424	93.4	
	6,689,757	02/10/2004	Craig	514	44	
	US 2004/0047867	03/11/2004	Capron et al.	424	184.1	

FOREIGN PATENT DOCUMENTS


EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	01/93906	13/12/2001	WO	A61K	39/39	<input type="checkbox"/>	<input type="checkbox"/>
	95/28486	26/10/1995	WO	C12N	15/31		
	96/31535	10/10/1996	WO	C07K	14/235		
	2 768 928	06/10/1998	FR				
	0 267 998	25/05/1988	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Keogh et al., "Induction of Antigen-Specific Regulatory T Cells by Coadministration of Peptides and Pathogen-Derived Molecules that Stimulate Dendritic Cell IL-10 Production", Immunology 107: Suppl 1, Abstract 1.14 (December 2002).
	McGuirk et al., "Pathogen-Specific Regulatory T Cells Provoke a Shift in the Th1/Th2 Paradigm in Immunity to Infectious Diseases", Trends in Immunology, vol. 23, no. 9, September 2002. pp. 450-455.

EXAMINER
DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO. 43369-0001		SERIAL NO. 10/575,291			
		APPLICANT: Kingston Mills et al					
		FILING DATE: 4/11/2004		GROUP: Unassigned			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	McGuirk et al., "Pathogen-Specific T Regulatory 1 Cells Induced in the Respiratory Tract by a Bacterial Molecule that Stimulates Interleukin 10 Production by Dendritic Cells: A Novel Strategy for Evasion of Protective T Helper Type 1 Responses by <i>Bordetella Pertussis</i> ", J. Exp. Med-The Rockefeller University Press, 0022-1007/2002/01/221/11, vol. 195, no. 2, January 21, 2002, pp. 221-231.						
	McGuirk et al., "Filamentous Hemagglutinin and Pertussis Toxin from <i>Bordetella Pertussis</i> Modulate Immune Responses to Unrelated Antigens", The Journal of Infectious Diseases, 2000;182: pp/1286-1288.						
	McGuirk et al., "Direct Anti-Inflammatory Effect of a Bacterial Virulence Factor: IL-10 Dependent Suppression of IL-12 Production by Filamentous Hemagglutinin from <i>Bordetella Pertussis</i> ", Eur. J. Immunol., 2000.30:, pp.415-422.						
	Poulain-Godefroy et al., "Adjuvant Activity of Free Bordetella Pertussis Filamentous Haemagglutinin Delivered by Mucosal Routes", Scandinavian Journal of Immunology 58, pp. 503-510.						
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.